Vigmed granted an additional patent for CLiP®

The Swedish Patent and Registration Office (PRV) has announced to Vigmed that it intends to grant the Company an additional patent for their needle protecting solution CLiP®.

Vigmed has earlier been granted patent for the needle protecting solution CLiP®, and I.V. systems comprising CLiP®. This patent will broaden Vigmed’s scope of protection, since it gives Vigmed protection for another feature of CLiP®, and regardless of field of application. An international patent application is also filed.

Vigmed has filed nationally and internationally more than 60 patents and patent applications based on three innovation platforms. The company owns all its patents and patent applications without any restrictions. The basic patents all have a maximum validity period.

Vigmeds strategy is to protect the Company's technology and products in all geographical areas deemed to be of importance. Vigmed intends to expand its patent portfolio continuously on both the offensive and defensive patent and utility model rights based on a number of new innovation platforms.

For further information contact:

Chairman of the board, Lennart Holm +46 70 630 8562 or CEO, Finn Ketler +46 42 600 5311

Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden, and has approximately 20 employees. Vigmed’s share is traded on NASDAQ OMX First North in Stockholm (ticker VIG) and has approximately 5 400 shareholders. Remium Nordic AB is the Company’s Certified Advisor.

Additional information such as company description, a video presentation and risk factors can be found on Vigmed’s website: www.vigmed.com/investor

Tags: